Shingrix Decreases Shingles Incidence in Blood Ca Patients Post-Transplant
Patients who underwent autologous hematopoietic stem cell transplantation (HSCT) and received the recombinant herpes zoster vaccine (Shingrix) had a lower incidence of the illness compared with HSCT patients receiving placebo, noted a randomized trial.During a median follow-up of 21 months, there was at least one herpes zoster case confirmed in 49 patients who received the vaccine and in 135 patients who received placebo (incidence rate ratio 0.32, 95% CI 0.22-0.44, P<0.001)
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies